ea0047oc32 | Spotlight on Prostate Cancer | Theranostics2016
Kulkarni Harshad R.
, Singh Aviral
, Schuchardt Christiane
, Niepsch Karin
, Baum Richard P.
Aim: To analyze the safety, efficacy and dosimetry of Lu-177 labeled prostate specific membrane antigen (PSMA) ligand 617 in patients with progressive metastatic castration-resistant prostate cancer (mCRPC), in comparison with Lu-177 PSMA I&T.Methods: Lu-177 PSMA-617 radioligand therapy (PRLT) was performed in 64 mCRPC patients. The median administered activity per treatment was 6 GBq. Ga-68 PSMA PET/CT was used for patient selection and follow-up. H...